This study aims to develop and examine the feasibility and preliminary effectiveness of an AI-based sarcoma chatbot building on ChatGPT (ASCC) to address the information needs of sarcoma patients. We hypothesized: 1) the ASCC will demonstrate good usability; 2) the study will be feasible in terms of all feasibility indicators; 3) the experimental group will report improved satisfaction and self-efficacy, decreased anxiety and stress than the control groups upon completion of the intervention. The ASCC will be developed using a co-design approach. A pilot randomized controlled trial will then be conducted in the three oncology wards of collaborative hospitals. Seventy-eight sarcoma patients will be recruited and randomized to the experimental group (n=39) and the control group (n=39). The experimental group will use the ASCC available 24/7 via voice or text for disease-related questions for one month while the control group will receive usual care.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Screening rate
Timeframe: During the enrollment period of this project.
Eligibility rate
Timeframe: During the enrollment period of this project.
Consent rate
Timeframe: During the enrollment period of this project.
Randomization rate
Timeframe: During the enrollment period of this project.
Attendance rate
Timeframe: Baseline and immediately after intervention (T1)
Retention rate
Timeframe: Baseline and immediately after intervention (T1)
Completion rate
Timeframe: Baseline and immediately after intervention (T1)
Proportion of missing data
Timeframe: Baseline and immediately after intervention (T1)
Adverse events
Timeframe: immediately after intervention (T1)